These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28000523)

  • 1. CXCR2 inhibition in pancreatic cancer: opportunities for immunotherapy?
    Morton JP; Sansom OJ
    Immunotherapy; 2017 Jan; 9(1):9-12. PubMed ID: 28000523
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation and modulation of antitumor immunity in pancreatic cancer.
    Leinwand J; Miller G
    Nat Immunol; 2020 Oct; 21(10):1152-1159. PubMed ID: 32807942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Steele CW; Karim SA; Leach JDG; Bailey P; Upstill-Goddard R; Rishi L; Foth M; Bryson S; McDaid K; Wilson Z; Eberlein C; Candido JB; Clarke M; Nixon C; Connelly J; Jamieson N; Carter CR; Balkwill F; Chang DK; Evans TRJ; Strathdee D; Biankin AV; Nibbs RJB; Barry ST; Sansom OJ; Morton JP
    Cancer Cell; 2016 Jun; 29(6):832-845. PubMed ID: 27265504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Part II: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
    Kimbara S; Kondo S
    World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint therapy for pancreatic cancer.
    Johansson H; Andersson R; Bauden M; Hammes S; Holdenrieder S; Ansari D
    World J Gastroenterol; 2016 Nov; 22(43):9457-9476. PubMed ID: 27920468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
    Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report.
    Bertelli G; Trovato R; Ugel S; Bria E; Milella M; Bronte V; Pilotto S
    Clin Lung Cancer; 2019 Jul; 20(4):e514-e516. PubMed ID: 31122866
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-L1 Expression in Pancreatic Cancer.
    Zheng L
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131993
    [No Abstract]   [Full Text] [Related]  

  • 15. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.
    Skelton RA; Javed A; Zheng L; He J
    J Surg Oncol; 2017 Jul; 116(1):55-62. PubMed ID: 28628715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
    Kieler M; Unseld M; Bianconi D; Prager G
    Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR2 inhibition suppresses acute and chronic pancreatic inflammation.
    Steele CW; Karim SA; Foth M; Rishi L; Leach JD; Porter RJ; Nixon C; Jeffry Evans TR; Carter CR; Nibbs RJ; Sansom OJ; Morton JP
    J Pathol; 2015 Sep; 237(1):85-97. PubMed ID: 25950520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches tackle rising pancreatic cancer rates.
    Brower V
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25535299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.